Briefly noted: O Courbette et al. JPGN 2019; 69: 189-93. In a retrospective review, among 147 children with inflammatory bowel disease treated with infliximab (IFX) (123 CD, 24 UC), 20 patients (13.6%) developed psoriaform rashes. 14 of 20 were in remission when skin rashes (especially on scalp) occurred and rash developed at median of 355 days. In this cohort, all were controlled by local steroids; no patients required IFX discontinuation.
Related blog posts:
- Practice Tips for New IBD Therapies “One of the points alluding to in this chart is that addition of methotrexate may help in patients receiving anti-TNF therapy with psoriasis.”
- Pattern of Skin Reactions to Anti-TNF Agents | gutsandgrowth
- IBD Shorts -Skin, Adalimumab Kinetics | gutsandgrowth
- Characteristics of Skin Lesions Associated with Anti-Tumor Necrosis Factor Therapy | gutsandgrowth
- Immune-Mediated Reactions to Anti-TNFs and What to Do About Them | gutsandgrowth